Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 2454 participants.

Also called NCT01481116

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 2,454 participants (enrolled count) (from the registry)
Sponsor
  • Takeda Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01481116
  • EudraCT 2011-001731-24
  • WHO UTN U1111-1124-2296
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Bulgaria, Canada, Colombia, Czechia, Estonia, Hong Kong SAR China, Israel, Latvia, Lithuania, Malaysia, Mexico, New Zealand, Philippines, Poland, Romania, Russia, South Africa, Taiwan, Ukraine, United Kingdom (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT01481116. Randomized; quadruple masking; primary purpose treatment. Start 2012-01 (registry gives no type); primary completion 2014-03 (actual). Results posted on 2016-06-01.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
TAK-875
Intervention (Drug)
TAK-875
Intervention (Drug)
Glimepiride
Lead sponsor
Takeda (class: industry)

Record details

Record id
cardio:ct-nct01481116
Content hash
7d364e0d91a52a095df799fa3b7f57fe0f61e553e40185999b1c897ec317e6b3